MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury

References

• Alfirevic A, Pirmohamed M. Genomics of adverse drug reactions. Trends Pharmacol Sci. 2017;38(1):100–109.
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Bernal W. Update on acute liver failure. Curr Opin Crit Care. 2015;21(2):134–141.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi PH, Gu JZ, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–U189.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–514.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–U437.
   PubMed Web of Science ®Google Scholar
• Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one? J Pharmacol Exp Ther. 2010;332(3):692–697.
   PubMed Web of Science ®Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010;51(6):2117–2126.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J. 2005;172(3):367–379.
   PubMed Web of Science ®Google Scholar
• Padda MS, Sanchez M, Akhtar AJ, et al. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–1387.
   PubMed Web of Science ®Google Scholar
• Regev A, Bjornsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147(1):20–24.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–489.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52.e7.
   PubMed Web of Science ®Google Scholar
• Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–U204.
   PubMed Web of Science ®Google Scholar
• Nathwani RA, Pais S, Reynolds TB, et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology. 2005;41(2):380–382.
   PubMed Web of Science ®Google Scholar
• Sarac F, Saygili F. Causes of high bone alkaline phosphatase. Biotechnology & Biotechnological Equipment. 2007;21(2):194–197.
   Web of Science ®Google Scholar
• Mukaiyama K, Kamimura M, Uchiyama S, et al. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res. 2015;27(4):413–418.
   PubMed Web of Science ®Google Scholar
• Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017;37:1582–1590.
   PubMed Web of Science ®Google Scholar
• Robles-Diaz M, Medina-Caliz I, Stephens C, et al. Biomarkers in DILI: one more step forward. In: Frontiers in Pharmacology. 2016. p. 7:267.
   Google Scholar
• Longo DM, Generaux GT, Howell BA, et al. Refining liver safety risk assessment: application of mechanistic modeling and serum biomarkers to Cimaglermin Alfa (GGF2) clinical trials. Clin Pharmacol Ther. 2017;102(6):961-969.
   Web of Science ®Google Scholar
• Knopp RH, Brown WV, Corder CN, et al. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med. 1993;153(11):1321–1329.
   PubMedGoogle Scholar
• Dukes GE, Sanders SW, Russo J, et al. Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med. 1984;100(5):646–650.
   PubMed Web of Science ®Google Scholar
• Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis. 2015;33(4):464–471.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Harrill AH, Watkins PB, et al. Safety biomarkers for drug-induced liver injury - current status and future perspectives. Toxicol Res (Camb). 2014;3(2):75–85.
   Web of Science ®Google Scholar
• Wang J, Chen JY, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30.
   PubMed Web of Science ®Google Scholar
• Kim Y-K, Kim B, Kim VN. Re-evaluation of the roles of DROSHA, Exportin 5, and DICER in microRNA biogenesis. Proc Natl Acad Sci U S A. 2016;113(13):E1881–E9.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–477.
   PubMed Web of Science ®Google Scholar
• Meunier J, Lemoine F, Soumillon M, et al. Birth and expression evolution of mammalian microRNA genes. Genome Res. 2013;23(1):34–45.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Pfeffer S, Baumert TF, et al. miR-122-A key factor and therapeutic target in liver disease. J Hepatol. 2015;62(2):448–457.
   PubMed Web of Science ®Google Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98.
   PubMed Web of Science ®Google Scholar
• Boix L, Lopez-Oliva JM, Rhodes AC, et al. Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-beta pathway. Oncotarget. 2016;7(44):71309–71329.
   PubMed Web of Science ®Google Scholar
• Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 2009;23(11):1313–1326.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang SL, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402–4407.
   PubMed Web of Science ®Google Scholar
• Lewis PJS, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767–1776.
   PubMed Web of Science ®Google Scholar
• Tamai S, Iguchi T, Niino N, et al. A monkey model of acetaminophen-induced hepatotoxicity; phenotypic similarity to human. J Toxicological Sci. 2017;42(1):73–84.
   PubMed Web of Science ®Google Scholar
• Vliegenthart ADB, Lewis PS, Cs T, et al. Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity. Zebrafish. 2014;11(3):219–226.
   PubMed Web of Science ®Google Scholar
• Lopez-Riera M, Conde I, Tolosa L, et al. New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease. Front Pharmacol. 2017;8:3.
   PubMed Web of Science ®Google Scholar
• Dear JW, Antoine DJ, Starkey-Lewis P, et al. Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br J Clin Pharmacol. 2014;77(5):904–905.
   PubMed Web of Science ®Google Scholar
• Vliegenthart ADB, Shaffer JM, Clarke JI, et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep. 2015;5:15501.
   PubMed Web of Science ®Google Scholar
• Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017;37(5):757–764.
   PubMed Web of Science ®Google Scholar
• Hornby RJ, Lewis PS, Dear J, et al. MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. Expert Rev Clin Pharmacol. 2014;7(3):349–362.
   PubMed Web of Science ®Google Scholar
• Vliegenthart AD, Berends C, Potter CM, et al. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol. 2017;83(9): 2027–2033.
   Web of Science ®Google Scholar
• Feng C, Mao X, Shi H, et al. Detection of microRNA: a point-of-care testing method based on a pH-responsive and highly efficient isothermal amplification. Anal Chem. 2017;89(12):6631–6636.
   PubMed Web of Science ®Google Scholar
• Vaca L. Point-of-care diagnostic tools to detect circulating microRNAs as biomarkers of disease. Sensors. 2014;14(5):9117–9131.
   PubMed Web of Science ®Google Scholar
• Tavallaie R, De Almeida SRM, Gooding JJ. Toward biosensors for the detection of circulating microRNA as a cancer biomarker: an overview of the challenges and successes. Wiley Interdisciplinary Reviews-Nanomedicine Nanobiotechnology. 2015;7(4):580–592.
   PubMed Web of Science ®Google Scholar
• Campuzano S, Pedrero M, Pingarron JM. Electrochemical genosensors for the detection of cancer-related miRNAs. Anal Bioanal Chem. 2014;406(1):27–33.
   PubMed Web of Science ®Google Scholar
• Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014;34(3):367–378.
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–3536.
   PubMed Web of Science ®Google Scholar
• Luna JM, Scheel TKH, Danino T, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell. 2015;160(6):1099–1110.
   PubMed Web of Science ®Google Scholar
• Woolbright BL, Antoine DJ, Jenkins RE, et al. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol. 2013;273(3):524–531.
   PubMed Web of Science ®Google Scholar
• Farid WRR, Pan QW, van der Meer AJP, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transplant. 2012;18(3):290–297.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Gianotti TF, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812.
   PubMed Web of Science ®Google Scholar
• Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A. 2014;111(33):12169–12174.
   PubMed Web of Science ®Google Scholar
• Krauskopf J, de Kok TM, Schomaker SJ, et al. Serum microRNA signatures as “liquid biopsies” for interrogating hepatotoxic mechanisms and liver pathogenesis in human. Plos One. 2017;12:5.
   Web of Science ®Google Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154–1164.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Bala S, Kodys K, et al. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. Sci Rep. 2015;5:09991.
   Web of Science ®Google Scholar
• Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56(5):1946–1957.
   PubMed Web of Science ®Google Scholar
• Yamaura Y, Nakajima M, Tatsumi N, et al. Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs. Toxicology. 2014;322:89–98.
   PubMed Web of Science ®Google Scholar
• Stutchfield BM, Antoine DJ, Mackinnon AC, et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology. 2015;149(7):1896–+.
   PubMed Web of Science ®Google Scholar
• Castro RE, Ferreira DMS, Zhang XX, et al. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiology-Gastrointestinal Liver Physiol. 2010;299(4):G887–G97.
   PubMed Web of Science ®Google Scholar
• Chen XY, Song MY, Chen W, et al. MicroRNA-21 contributes to liver regeneration by targeting PTEN. Med Sci Monitor. 2016;22:83–91.
   PubMed Web of Science ®Google Scholar
• Park HK, Jo W, Choi HJ, et al. Time-course changes in the expression levels of miR-122,-155, and-21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci. 2016;17(1):45–51.
   PubMed Web of Science ®Google Scholar
• Juskeviciute E, Dippold RP, Antony AN, et al. Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats. Am J Physiology-Gastrointestinal Liver Physiol. 2016;311(5):G794–G806.
   PubMed Web of Science ®Google Scholar
• Sekine S, Ogawa R, McManus MT, et al. Dicer is required for proper liver zonation. J Pathol. 2009;219(3):365–372.
   PubMed Web of Science ®Google Scholar
• Lindros KO. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen Pharmacol. 1997;28(2):191–196.
   PubMedGoogle Scholar
• Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol. 2001;14(6):694–701.
   PubMed Web of Science ®Google Scholar
• Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008;12(1):203-+.
   PubMed Web of Science ®Google Scholar
• Yamaura Y, Nakajima M, Takagi S, et al. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. Plos One. 2012;7(2).
   Web of Science ®Google Scholar
• Church RJ, Otieno M, McDuffie JE, et al. Beyond miR-122: identification of microRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia in rats. Toxicological Sci. 2016;150(1):3–14.
   PubMed Web of Science ®Google Scholar